Robert N Schuck (Robert Schuck)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 12

Top Topics

Bariatric Surgery

Epidermal Growth Factor Receptor

Drug Administration

Top Venues

Clinical pharmacology and therapeutics

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

Orphanet journal of rare diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Zachary L Taylor, Francis G Green, Nayeem Hossain, Gilbert J Burckart, Michael Pacanowski, Robert N Schuck
Assessment of Dosing Strategies for Pediatric Drug Products. Clinical pharmacology and therapeutics 116 (3) (2024)
Mirat Shah, Hima Lingam, Xin Gao, Haley Gittleman, Mallorie H Fiero, Danielle Krol, Nikolett Biel, Tiffany K Ricks, Wentao Fu, Salaheldin Hamed, Fang Li, Jillian Jielin Sun, Jianghong Fan, Robert N Schuck, Manuela Grimstein, Liuya Tang, Shyam Kalavar, Abdelrahmman Abukhdeir, Anand Pathak, Soma Ghosh, Ilynn Bulatao, Amy Tilley, William F Pierce, Bronwyn D Mixter, Shenghui Tang, Richard Pazdur, Paul Kluetz, Laleh Amiri-Kordestani
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1 -Mutated Advanced or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Zachary L Taylor, Francis G Green, Nayeem Hossain, Gilbert J Burckart, Michael Pacanowski, Robert N Schuck
Assessment of Dosing Strategies for Pediatric Drug Products. Clinical pharmacology and therapeutics (2024)
Zachary L Taylor, Francis G Green, Nayeem Hossain, Gilbert J Burckart, Michael Pacanowski, Robert N Schuck
Assessment of Dosing Strategies for Pediatric Drug Products. Clinical pharmacology and therapeutics (2024)
Zachary L Taylor, Francis G Green, Nayeem Hossain, Gilbert J Burckart, Michael Pacanowski, Robert N Schuck
Assessment of Dosing Strategies for Pediatric Drug Products. Clinical pharmacology and therapeutics 116 (3) (2024)
Mirat Shah, Hima Lingam, Xin Gao, Haley Gittleman, Mallorie H Fiero, Danielle Krol, Nikolett Biel, Tiffany K Ricks, Wentao Fu, Salaheldin Hamed, Fang Li, Jillian Jielin Sun, Jianghong Fan, Robert N Schuck, Manuela Grimstein, Liuya Tang, Shyam Kalavar, Abdelrahmman Abukhdeir, Anand Pathak, Soma Ghosh, Ilynn Bulatao, Amy Tilley, William F Pierce, Bronwyn D Mixter, Shenghui Tang, Richard Pazdur, Paul Kluetz, Laleh Amiri-Kordestani
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1 -Mutated Advanced or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (10) (2024)
Zachary L Taylor, Francis G Green, Nayeem Hossain, Gilbert J Burckart, Michael Pacanowski, Robert N Schuck
Assessment of Dosing Strategies for Pediatric Drug Products. Clinical pharmacology and therapeutics 116 (3) (2024)
Mirat Shah, Hima Lingam, Xin Gao, Haley Gittleman, Mallorie H Fiero, Danielle Krol, Nikolett Biel, Tiffany K Ricks, Wentao Fu, Salaheldin Hamed, Fang Li, Jillian Jielin Sun, Jianghong Fan, Robert N Schuck, Manuela Grimstein, Liuya Tang, Shyam Kalavar, Abdelrahmman Abukhdeir, Anand Pathak, Soma Ghosh, Ilynn Bulatao, Amy Tilley, William F Pierce, Bronwyn D Mixter, Shenghui Tang, Richard Pazdur, Paul Kluetz, Laleh Amiri-Kordestani
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1 -Mutated Advanced or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (10) (2024)
Jane P F Bai, Audra L Stinchcomb, Jie Wang, Justin Earp, Sydney Stern, Robert N Schuck
Creating a Roadmap to Quantitative Systems Pharmacology-Informed Rare Disease Drug Development: A Workshop Report. Clinical pharmacology and therapeutics (2023)
Oluseyi Adeniyi, Mary Hwang, Jielin Sun, Robert N Schuck
Premarket assessment of molecular alterations in drug targets: a case study of 2020 drug approvals. Pharmacogenomics 23 (7) (2022)
Lingshan Wang, Jie Wang, Ji Feng, Mary Doi, Salvatore Pepe, Michael Pacanowski, Robert N Schuck
Dose-finding studies in drug development for rare genetic diseases. Orphanet journal of rare diseases 17 (1) (2022)
Timil H Patel, Leigh Marcus, M Naomi Horiba, Martha Donoghue, Somak Chatterjee, Pallavi S Mishra-Kalyani, Robert N Schuck, Yangbing Li, Xinyuan Zhang, Jeanne F Zirkelbach, Rosane Charlab, Jiang Liu, Yuching Yang, Steven J Lemery, Richard Pazdur, Marc R Theoret, Lola A Fashoyin-Aje
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 fusion or other rearrangement. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)